News 23andMe ends drug development and slashes staff 23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.
News NICE backs AZ/Ionis' Wainzua for ATTR polyneuropathy AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the treatment of patients with ATTR polyneuropathy
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends